CZ353698A3 - Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje - Google Patents
Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje Download PDFInfo
- Publication number
- CZ353698A3 CZ353698A3 CZ983536A CZ353698A CZ353698A3 CZ 353698 A3 CZ353698 A3 CZ 353698A3 CZ 983536 A CZ983536 A CZ 983536A CZ 353698 A CZ353698 A CZ 353698A CZ 353698 A3 CZ353698 A3 CZ 353698A3
- Authority
- CZ
- Czechia
- Prior art keywords
- antibody
- seq
- sequence
- light chain
- humanized
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9609405.7A GB9609405D0 (en) | 1996-05-04 | 1996-05-04 | Protein |
| GBGB9703103.3A GB9703103D0 (en) | 1997-02-14 | 1997-02-14 | Protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ353698A3 true CZ353698A3 (cs) | 1999-02-17 |
Family
ID=26309272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ983536A CZ353698A3 (cs) | 1996-05-04 | 1997-04-29 | Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6277599B1 (enExample) |
| EP (1) | EP0896626B1 (enExample) |
| JP (1) | JP2000510692A (enExample) |
| CN (1) | CN1217750A (enExample) |
| AT (1) | ATE350478T1 (enExample) |
| AU (1) | AU719513B2 (enExample) |
| BR (1) | BR9708910A (enExample) |
| CA (1) | CA2250579A1 (enExample) |
| CZ (1) | CZ353698A3 (enExample) |
| DE (1) | DE69737188T2 (enExample) |
| ES (1) | ES2279539T3 (enExample) |
| HU (1) | HUP9901562A3 (enExample) |
| IL (1) | IL126772A0 (enExample) |
| NO (1) | NO985120L (enExample) |
| NZ (1) | NZ331978A (enExample) |
| PL (1) | PL329871A1 (enExample) |
| SK (1) | SK150298A3 (enExample) |
| TR (1) | TR199802227T2 (enExample) |
| WO (1) | WO1997042329A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000510692A (ja) * | 1996-05-04 | 2000-08-22 | ゼネカ リミテッド | Ｃｅａに対するモノクローナル抗体、その抗体を含む結合体、およびａｄｅｐｔシステムにおけるそれらの治療的使用 |
| WO1998035988A1 (en) * | 1997-02-14 | 1998-08-20 | Zeneca Limited | Proteins |
| GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| JP2002504372A (ja) * | 1998-02-25 | 2002-02-12 | ザ ダウ ケミカル カンパニー | 高親和性ヒト型化抗−ｃｅａモノクロ−ナル抗体 |
| JP2002530080A (ja) * | 1998-11-19 | 2002-09-17 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 免疫グロブリン・スーパーファミリー・タンパク質 |
| CA2355402A1 (en) * | 1998-12-21 | 2000-06-29 | Eli Lilly And Company | Recombinant synthesis of beta-lipotropin and other peptides |
| GB2371803A (en) * | 1999-11-18 | 2002-08-07 | Oxford Biomedica Ltd | Antibodies |
| JP2003515323A (ja) * | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ（ユーケイ）リミテッド | 抗 体 |
| ATE372130T1 (de) * | 2000-04-22 | 2007-09-15 | Pharmedartis Gmbh | Apoptotika |
| GB0210783D0 (en) * | 2002-05-10 | 2002-06-19 | Polonelli Luciano | Anti-microbial polypeptides |
| KR100604037B1 (ko) * | 2002-08-02 | 2006-07-24 | 주식회사유한양행 | 항체 경쇄 카파 발현벡터 |
| US20050008618A1 (en) * | 2003-02-27 | 2005-01-13 | Howard Kaufman | Composition for delivering an agent to a target cell and uses thereof |
| JP2006520610A (ja) * | 2003-03-04 | 2006-09-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ハイブリッド不変領域を産生するのに用いるベクター |
| EP2404615A1 (en) * | 2003-04-23 | 2012-01-11 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) |
| WO2005058236A2 (en) * | 2003-12-12 | 2005-06-30 | Genencor International, Inc. | Cab molecules |
| JP4805848B2 (ja) | 2004-02-12 | 2011-11-02 | モルフォテック、インク． | 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 |
| DE602005023138D1 (de) * | 2004-04-15 | 2010-10-07 | Genencor Int | Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept |
| CA2585776A1 (en) | 2004-10-29 | 2006-05-11 | University Of Southern California | Combination cancer immunotherapy with co-stimulatory molecules |
| WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
| US20060239910A1 (en) | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1942939B2 (en) | 2005-09-30 | 2021-07-07 | Medimmune Limited | Interleukin-13 antibody composition |
| US8993295B2 (en) | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| US8043830B2 (en) * | 2008-02-01 | 2011-10-25 | The Regents Of The University Of California | Biotin-ligase system for secretion of biotinylated protein |
| CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| CN101704892B (zh) * | 2009-12-09 | 2014-02-12 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗uPAR人源化抗体及其编码基因与应用 |
| SG182590A1 (en) | 2010-01-28 | 2012-08-30 | Glaxo Group Ltd | Cd127 binding proteins |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| CN102526707B (zh) * | 2012-01-13 | 2015-04-22 | 成都博发生物技术有限公司 | 共刺激因子及融合蛋白的新用途 |
| RU2493166C1 (ru) * | 2012-04-09 | 2013-09-20 | Общество с ограниченной ответственностью "Технофарма" | Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка |
| CN102838676A (zh) * | 2012-09-26 | 2012-12-26 | 李彬 | 一种癌胚抗原单抗及包含该抗体的芯片以及应用 |
| SI2766048T1 (sl) | 2012-10-12 | 2015-03-31 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| UA113129C2 (xx) | 2013-04-29 | 2016-12-12 | ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b | |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| IL251822B2 (en) | 2014-10-29 | 2023-03-01 | Teva Pharmaceuticals Australia Pty Ltd | Variants of interferon alpha-2-b |
| US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| CA3030926A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd47 combination therapy |
| EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| CN111533805B (zh) * | 2016-12-04 | 2022-02-08 | 深圳市国创纳米抗体技术有限公司 | 一种抗癌胚抗原的高亲和力纳米抗体及其应用 |
| SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| WO2021041725A1 (en) * | 2019-08-27 | 2021-03-04 | The Trustees Of The Univeristy Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13Rα2 POSITIVE HUMAN AND CANINE TUMORS |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| CN115850483B (zh) * | 2020-10-21 | 2025-09-19 | 北京纽安博生物技术有限公司 | 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| JP2000510692A (ja) * | 1996-05-04 | 2000-08-22 | ゼネカ リミテッド | Ｃｅａに対するモノクローナル抗体、その抗体を含む結合体、およびａｄｅｐｔシステムにおけるそれらの治療的使用 |
-
1997
- 1997-04-29 JP JP09539625A patent/JP2000510692A/ja active Pending
- 1997-04-29 IL IL12677297A patent/IL126772A0/xx unknown
- 1997-04-29 ES ES97918258T patent/ES2279539T3/es not_active Expired - Lifetime
- 1997-04-29 TR TR1998/02227T patent/TR199802227T2/xx unknown
- 1997-04-29 US US09/171,945 patent/US6277599B1/en not_active Expired - Fee Related
- 1997-04-29 SK SK1502-98A patent/SK150298A3/sk unknown
- 1997-04-29 CA CA002250579A patent/CA2250579A1/en not_active Abandoned
- 1997-04-29 EP EP97918258A patent/EP0896626B1/en not_active Expired - Lifetime
- 1997-04-29 CN CN97194390A patent/CN1217750A/zh active Pending
- 1997-04-29 AU AU26455/97A patent/AU719513B2/en not_active Ceased
- 1997-04-29 BR BR9708910A patent/BR9708910A/pt not_active Application Discontinuation
- 1997-04-29 PL PL97329871A patent/PL329871A1/xx unknown
- 1997-04-29 HU HU9901562A patent/HUP9901562A3/hu unknown
- 1997-04-29 WO PCT/GB1997/001165 patent/WO1997042329A1/en not_active Ceased
- 1997-04-29 NZ NZ331978A patent/NZ331978A/xx unknown
- 1997-04-29 CZ CZ983536A patent/CZ353698A3/cs unknown
- 1997-04-29 DE DE69737188T patent/DE69737188T2/de not_active Expired - Fee Related
- 1997-04-29 AT AT97918258T patent/ATE350478T1/de not_active IP Right Cessation
-
1998
- 1998-11-03 NO NO985120A patent/NO985120L/no not_active Application Discontinuation
-
2001
- 2001-07-23 US US09/910,059 patent/US6903203B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1217750A (zh) | 1999-05-26 |
| US6277599B1 (en) | 2001-08-21 |
| JP2000510692A (ja) | 2000-08-22 |
| BR9708910A (pt) | 1999-08-03 |
| WO1997042329A1 (en) | 1997-11-13 |
| EP0896626B1 (en) | 2007-01-03 |
| NZ331978A (en) | 2000-05-26 |
| SK150298A3 (en) | 1999-04-13 |
| ES2279539T3 (es) | 2007-08-16 |
| HUP9901562A2 (hu) | 1999-08-30 |
| AU2645597A (en) | 1997-11-26 |
| ATE350478T1 (de) | 2007-01-15 |
| HUP9901562A3 (en) | 2000-06-28 |
| IL126772A0 (en) | 1999-08-17 |
| AU719513B2 (en) | 2000-05-11 |
| PL329871A1 (en) | 1999-04-12 |
| DE69737188T2 (de) | 2007-10-11 |
| NO985120L (no) | 1998-12-29 |
| US20020142359A1 (en) | 2002-10-03 |
| NO985120D0 (no) | 1998-11-03 |
| CA2250579A1 (en) | 1997-11-13 |
| DE69737188D1 (de) | 2007-02-15 |
| EP0896626A1 (en) | 1999-02-17 |
| TR199802227T2 (xx) | 2000-07-21 |
| US6903203B2 (en) | 2005-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU719513B2 (en) | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system | |
| AU709503B2 (en) | Delivery system using mAb 3E10 and mutants and/or functional fragments thereof | |
| US8858950B2 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
| CA2019559C (en) | Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof | |
| KR101370164B1 (ko) | 신규 항ｃｄ98 항체 | |
| EP0731838B1 (en) | Binding structures directed against the ca55.1 antigen | |
| JP3805365B2 (ja) | 化合物 | |
| AU2004245038A1 (en) | De-immunized anti-CD3 antibody | |
| SK153599A3 (en) | Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety | |
| Hoogenboom et al. | Cloning and expression of a chimeric antibody directed against the human transferrin receptor. | |
| JPH11511970A (ja) | 化学化合物 | |
| KR20000010771A (ko) | Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도 | |
| CN100543135C (zh) | 单克隆抗体及编码其的基因、药物组合物和诊断试剂 | |
| JPH03254691A (ja) | 薬剤耐性癌に対するキメラ抗体およびその製造 | |
| CZ396599A3 (cs) | Genový konstrukt, který kóduje část zaměřující buňku a enzym aktivující proléčivo, pro použití jako léčivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic |